AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 111 min read$ATEC

Miles Patrick purchased $1.0M of ATEC

Miles Patrick (CEO) purchased 115,000 shares of Alphatec Holdings, Inc. (ATEC) at $8.81 ($1.01M total) on 2026-09-10.

Original reporting
SEC EDGAR · Miles Patrick
Published Sep 11, 2026, 12:58 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 1:25 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ATEC
Bullish
high confidence
Mentioned
$ATEC
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATECBullishMed
01

Why it matters

The CEO's purchase may be interpreted as a vote of confidence, influencing investor sentiment.

02

Market read

The insider purchase is a fresh, material event that could affect short-term trading decisions.

03

What to watch

Potential upcoming earnings or regulatory news not disclosed could affect the stock.

Relevance 7/10Novelty 8/10Timing: after-market 2026-09-10 filing

Background

Form 4 filing reveals insider transactions; such disclosures are primary sources of corporate activity.

Company-level read

Ticker impact

$ATECBullishHigh confidence
Context

CEO Miles Patrick bought 115,000 shares for $1.01M, increasing his stake to over 5.8 million shares.

Expected impact

Possible modest price uptick in the next trading session.

Evidence & confidence

CEO insider buying $1M is material for a mid-cap; markets often react positively to executive purchases.

Market effects

Sector

May signal confidence in the medical device sector, but limited broader impact.

Regional

Primarily U.S. market; minimal regional effect.

Global

Low global relevance.

Counterpoint

What could challenge this read

Insider buying could be a preemptive move before a pending negative catalyst.

Key entities

  • Company
    Alphatec Holdings, Inc.

    Medical device manufacturer.

  • Executive
    Miles Patrick

    CEO and Director of Alphatec.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ATEC insider trading history →

Related articles

AUG 16
$ATECMedAI 8/10

Alphatec (ATEC) Q2 2026 Earnings Call Transcript

Alphatec Holdings (NASDAQ:ATEC) reported Q2 2026 revenue of $214 million, up 15% year over year, with surgical revenue at $196 million, up 17%. Adjusted EBITDA rose to $36 million, up 53%, with GAAP gross margin 72.2%. Management reaffirmed full-year revenue guidance near $882 million and raised adjusted EBITDA guidance to about $140 million.

aol.com6 min
AUG 12
$ATECMed

Alphatec (ATEC) Q2 2026 Earnings Call Transcript

Alphatec Holdings (ATEC) reported Q2 2026 revenue of $214 million, up 15% year over year, with surgical revenue at $196 million, up 17%. Adjusted EBITDA rose 53% to $36 million, and GAAP gross margin was 72.2%. Management reaffirmed full-year revenue guidance near $882 million and raised adjusted EBITDA guidance to about $140 million.

fool.com7 min
AUG 6
$ATECMed

Alphatec Holdings, Inc. Q2 2026 Earnings Call Summary

Alphatec Holdings (ATEC) reported Q2 2026 results driven by 24% growth in new surgeon adoption and 20% procedural volume growth, lifting revenue 15%. Management kept full-year surgical revenue guidance at $805M and raised adjusted EBITDA guidance to $140M. It expects Q3 free cash flow of $4M to $6M and cites margin gains from inventory and supply chain efficiency.

yahoo.com6 min
AUG 4
$ATECMed

Alphatec Holdings, Inc. (ATEC): Results of Operations and Financial Condition

Alphatec Holdings, Inc. (ATEC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ATEC Reports Second Quarter Financial Results Total revenue of $214 million, up 15% year-over-year Surgical revenue of $196 million increased 17%, driven by 20% case volume growth Company reaffirms 2026 revenue outlook CARLSBAD, Calif., August 4, 2026 – Alphatec Hold

SEC EDGAR 8-K6 min